TCM
BSX icon

Triumph Capital Management’s Boston Scientific BSX Stock Holding History

Triumph Capital Management’s Portfolio BSX Stock Details BSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.56K Sell
60
-43
-42% -$2.33K ﹤0.01% 1529
2026
Q1 		$6.46K Buy
103
+54
+110% +$4.32K ﹤0.01% 1230
2025
Q4 		$4.67K Buy
+49
New +$4.8K ﹤0.01% 1285

Other funds holding BSX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Triumph Capital Management's BSX Position: Q2 2026 in Review

Triumph Capital Management reduced its Boston Scientific (BSX) stake by 42% in Q2 2026, selling an estimated $2.33K and leaving 60 shares worth $2.56K. The position accounts for ﹤0.01% of the portfolio, ranked #1529.

Triumph Capital Management first reported a position in BSX in Q4 2025 and has held it in 3 quarters since. The position peaked at $6.46K in Q1 2026. 1,482 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

  • Triumph Capital Management held 60 shares of Boston Scientific worth $2.56K as of Q2 2026.
  • Triumph Capital Management sold 43 Boston Scientific shares in Q2 2026, an estimated $2.33K.
  • Boston Scientific made up ﹤0.01% of Triumph Capital Management's portfolio in Q2 2026, its #1529 holding.
  • Triumph Capital Management first reported a position in Boston Scientific in Q4 2025 and has held it in 3 quarters since.
  • Triumph Capital Management's Boston Scientific position peaked at $6.46K in Q1 2026.
  • 1,482 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on Triumph Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.